Table 1 Baseline characteristics of the AML cohort (N = 32)
Characteristic | Value |
|---|---|
Age (years) | 74 [61–86] |
 ≥ 75 years | 14 (44) |
WBC (× 109/L) | 2.5 [0.9–26.9] |
Platelets (× 109/L) | 30.0 [8.0–354.0] |
Bone marrow blasts (%) | 29.5 [14.0–86.0] |
AML subtype | |
Therapy-related AML (without antecedent myeloid disorder) | 6 (19) |
Prior MDS, MDS/MPN, or MPN | 22 (69) |
AML-MRC (without antecedent myeloid disorder) | 4 (13) |
Prior HMA or chemotherapy exposure for antecedent myeloid disorder | 17 (53) |
Cytogenetics | |
Complex | 12 (38) |
MECOM-rearranged* | 4 (13) |
Other adverse (non-complex, non-MECOM) | 6 (19) |
Diploid | 6 (19) |
Others (non-adverse) | 4 (13) |
Mutations# | |
ASXL1 | 7 (22) |
BCOR | 4 (13) |
CEBPA | 7 (22) |
CSF3R | 3 (10) |
DNMT3A | 5 (16) |
EZH2 | 3 (10) |
KRAS/NRAS | 8 (25) |
NF1 | 6 (19) |
PTPN11 | 3 (10) |
RUNX1 | 10 (31) |
SRSF2 | 5 (16) |
STAG2 | 4 (13) |
TET2 | 11 (34) |
TP53 | 11 (34) |
ZRSR2 | 3 (10) |
ELN 2017 cytomolecular risk | |
Favorable | 0 |
Intermediate | 5 (16) |
Adverse | 27 (84) |